Hospitals and clinical centres at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
48 hospitals and clinical centres are at ESGCT 2026 — 138 presentations on the program. Most represented: University Medical Center Hamburg-Eppendorf (23 on the program), Charité – Universitätsmedizin Berlin (15 on the program), San Raffaele Hospital (8 on the program). 21 of them have their own page in this guide. As of Oct 16, 2026.
Topic
Top represented
Showing 1–3 of 48 organizations
| Organization | ESGCT 2026 Attendance |
|---|---|
University Medical Center Hamburg-Eppendorf Hamburg, Germany | |
University medical center in Hamburg, Germany, combining hospital care with medical research and teaching. | Chair Tue Oct 27 5:00pm–7:30pm SESSION 2a: AAVs/Non integrative vectors I - Basic Vectors and delivery (AAV, lentiviral, LNP) Talk Wed Oct 28 12:15pm–12:30pm A Lentiviral Reporter System for HLA-Restricted Viral CD8+ T-Cell Epitope Screening Vectors and delivery (AAV, lentiviral, LNP) Poster Wed Oct 28 1:30pm–3:30pm A nanobody‑based immunoassay for quantifying AAV8/9‑derived VLPs and engineered AAV vectors Poster Wed Oct 28 1:30pm–3:30pm AAV capsid engineering for podocyte-specific targeting Poster Wed Oct 28 1:30pm–3:30pm Bispecific nanobody-based adaptors boost cell-specific AAV transduction Poster Wed Oct 28 1:30pm–3:30pm Computational Protein Design of AAV Vectors for Kidney Cell-Type-Specific Targeting Poster Wed Oct 28 1:30pm–3:30pm Engineering Kidney-Specific AAV8 Vectors via Combined Rational Design and In Vivo Directed Evolution Poster Wed Oct 28 1:30pm–3:30pm Enhanced transient CAR expression in resting primary T cells through mRNA-LNP optimization Poster Wed Oct 28 1:30pm–3:30pm Evaluating the Therapeutic Potential of gamma delta T-cells and Blinatumomab in Extramedullary Leukemia Poster Wed Oct 28 1:30pm–3:30pm Normothermic ex vivo perfusion of solid human tumors for the selection of tumor-targeting AAV vectors Poster Wed Oct 28 1:30pm–3:30pm Shear Stress Modulates AAV-Mediated Gene Transfer in Human Endothelial Cells Poster Thu Oct 29 2:00pm–4:00pm Automated production of gene-edited CAR-T Cells for people living with HIV Poster Thu Oct 29 2:00pm–4:00pm Bringing the THUNDER: Highlighting Multiparatopic CAR Cells for Multiple Myeloma Treatment Poster Thu Oct 29 2:00pm–4:00pm CAR-NK cells targeting both CD45 and CD38 Poster Thu Oct 29 2:00pm–4:00pm Cross-species AAV targeting of glomerular endothelial cells with inducible expression control Poster Thu Oct 29 2:00pm–4:00pm Establishment and evaluation of a negative selection protocol to improve the purity of lentiviral vector-based libraries for single-cell analyses using beta-2,6-fructosyltransferase (sacB) from B. subtilis Poster Thu Oct 29 2:00pm–4:00pm In Vivo CRISPR Surfaceome Screening Identifies the Entry Receptor for Glomerular Endothelial-Targeted AAV Vectors. Poster Thu Oct 29 2:00pm–4:00pm Nanobody-displaying AAV vectors that target glioblastoma brain tumors Poster Thu Oct 29 2:00pm–4:00pm Novel Bispecific T- and NK-Cell Engagers for the Depletion of IgE-Expressing Cells in Allergy Poster Thu Oct 29 2:00pm–4:00pm Optimization of ex vivo culture and lentiviral transduction conditions for murine Fanconi anemia hematopoietic stem and progenitor cells Poster Thu Oct 29 2:00pm–4:00pm Specific transduction of skeletal muscles and heart in vivo with Nanobody-displaying AAV Poster Thu Oct 29 2:00pm–4:00pm Twice as nice: Biparatopic CD229-specific VHH-based heavy-chain antibodies for the treatment of multiple myeloma Cancer gene and cell therapy Poster Thu Oct 29 2:00pm–4:00pm Uncovering tumor-intrinsic immune evasion in neuroblastoma using 3D spheroids Talk Thu Oct 29 5:00pm–6:00pm Discovery and initial characterization of a missense mutation (G1312A; E438K) in a signalling motif of the axi-cel and brexu-cel CD19-CARs present at high frequency in probably all clinical products Cell therapies and CAR-TCancer gene and cell therapy |
Charité – Universitätsmedizin Berlin Berlin, Germany | |
Berlin's university hospital and medical faculty, with research and trials in cell and gene therapy, including engineered T cells. | Talk Tue Oct 27 6:00pm–7:30pm Adenine base editing of FKBP12 and NR3C1 creates tacrolimus- and glucocorticoid-resistant T cells and Tregs for transplant immunotherapy Gene and epigenome editingCell therapies and CAR-T Poster Wed Oct 28 1:30pm–3:30pm Clinical development of tacrolimus-resistant regulatory T cells to enable simultaneous immunosuppression and immune regulation Poster Wed Oct 28 1:30pm–3:30pm Computational structure prediction guides rational design of enhanced CARs targeting a membrane-proximal epitope of IgA1 Poster Wed Oct 28 1:30pm–3:30pm Lipid nanoparticle-mediated multiplex engineering for virus free and scalable ex vivo manufacturing of T cells Poster Wed Oct 28 1:30pm–3:30pm Modulated CD3z signaling enhances persistence and tumor control of non-viral TRAC-integrated FcRL5-CAR T cells for MM and CLL Poster Wed Oct 28 1:30pm–3:30pm Multidimensional Evaluation of TCE-09B, a Novel Serum-Free Medium for Non-Viral CAR-T Cell Manufacturing Poster Wed Oct 28 1:30pm–3:30pm Scalable GMP-compliant manufacturing of T-cell products using semi-closed and automated bioreactors Poster Wed Oct 28 1:30pm–3:30pm Toward Off-the-Shelf Treg Therapies: Integrating Immunogenicity Prediction and Functional Validation Platforms Cell therapies and CAR-T Poster Thu Oct 29 2:00pm–4:00pm Combinatorial CD4+ and CD8+ TCR-T Cell therapy enhances anti-tumor responses to mutant p53 Poster Thu Oct 29 2:00pm–4:00pm Development and Comprehensive Characterization of GMP-Compliant Effector T Cells for Advanced Adoptive T-Cell Therapy Poster Thu Oct 29 2:00pm–4:00pm Establishment of a PTLD infection model and functional analysis of EBV-specific T-cells Poster Thu Oct 29 2:00pm–4:00pm Multiplex gene-edited "off the shelf" CAR T cells resist allo-rejection and glucocorticoid co-treatment Poster Thu Oct 29 2:00pm–4:00pm Optimizing Functional Assays for the Evaluation of regulatory T Cell product candidates Cell therapies and CAR-T Poster Thu Oct 29 2:00pm–4:00pm Pooled knock-in screening reveals principles for improved CAR T-cell design Talk Fri Oct 30 12:30pm–1:00pm One-pot PASTA: A CRISPR-integrase platform for efficient, site-specific integration of large transgenes in primary human T cells Gene and epigenome editingCell therapies and CAR-T |
San Raffaele Hospital Milan, Italy | |
Research hospital in Milan that hosts SR-Tiget and runs gene and cell therapy clinical trials. | Poster Wed Oct 28 1:30pm–3:30pm AAV9-mediated gene therapy to treat inherited CMT neuropathies with aberrant myelin Poster Wed Oct 28 1:30pm–3:30pm DUAL-SPECIFICITY PEPTIDE-GUIDED CAR T CELLS TARGET AVB6/AVB8 INTEGRINS FOR THERAPY, IMAGING, AND TUMOR MICROENVIRONMENT REMODELING IN PANCREATIC CANCER Poster Wed Oct 28 1:30pm–3:30pm Uncover and overcome senescence and dysfunction of genetically engineered lymphocytes for cancer immunotherapy Talk Thu Oct 29 11:15am–1:00pm Talk Thu Oct 29 12:15pm–1:00pm Poster Thu Oct 29 2:00pm–4:00pm Anti-aVB6/aVB8 integrins peptide-driven recombinant receptors for the engineering of anti-cancer living drugs Poster Thu Oct 29 2:00pm–4:00pm Use of etuvetidigene autotemcel in patients affected by Wiskott-Aldrich Syndrome in an early access setting Chair Fri Oct 30 2:30pm–4:30pm SESSION 13 Cancer models & gene therapy Cancer gene and cell therapy Talk Fri Oct 30 3:00pm–4:30pm SESSION 13 Cancer models & gene therapy Cancer gene and cell therapy |
Instantly find 20 buyers from hospitals and clinical centres
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ESGCT 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction